ReviewHuman mutation2026
A 2004-2025 Bibliometric Study of Genetic Variation and Multiomics Biomarkers in Sepsis Based on 940 Publications.
Review in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a highly heterogeneous syndrome, and conventional clinical indicators and single biomarkers often fail to capture its biological complexity or support precise risk stratification. To clarify the development of research in this area, this bibliometric study analyzed the literature on the clinical translation of genetic variation and multiomics biomarkers in sepsis. Publications were retrieved from PubMed, Web of Science Core Collection, and Scopus for the period from 2004 to 2025, and 940 eligible records were analyzed using Bibliometrix, VOSviewer, and CiteSpace. The results showed rapid expansion of the field, with annual output increasing from 1 publication in 2004 to 185 in 2025. China and the United States emerged as the leading contributors, while major institutions and journals reflected strong interdisciplinary collaboration across critical care, molecular biology, and translational medicine. The knowledge structure of the field has evolved from early emphasis on polymorphisms, susceptibility, and conventional inflammatory biomarkers toward metabolomics, transcriptomics, genomics, precision medicine, machine learning, and Mendelian randomization. At the same time, clinically relevant themes such as mortality, septic shock, acute kidney injury, and neonatal sepsis have remained central. These findings map a research trajectory from exploratory biomarker discovery toward translational frameworks for sepsis endotyping, prognostic evaluation, and risk stratification, but they should not be interpreted as evidence that the identified biomarkers or models are already clinically implemented. Future progress will depend on multicenter prospective validation, standardized analytic pipelines, broader population representation, and clinically deployable models that can translate molecular heterogeneity into real-world decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.